These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20334788)

  • 1. [Maintenance treatment of non-small cell lung cancer].
    Hansen O; Schytte T
    Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-line therapeutic options in non-small-cell lung cancer.
    Vansteenkiste J
    Lung Cancer; 2006 Dec; 54 Suppl 2():S15-8. PubMed ID: 17064813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 4. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
    Paesmans M; Berghmans T; Sculier JP
    Lung Cancer; 2007 Feb; 55(2):135-6. PubMed ID: 17118490
    [No Abstract]   [Full Text] [Related]  

  • 5. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The TULUNG clinical registry].
    Spelda S; Skřičková J; Bortlíček Z; Hejduk K; Pešek M; Zatloukal P; Kolek V; Salajka F; Koubková L; Tomíšková M; Grygárková Y; Havel L; Hrnčiarik M; Zemanová M; Sixtová D; Roubec J; Coupková H; Košatová K
    Klin Onkol; 2012; 25(5):383-4. PubMed ID: 23102201
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintenance therapy in non-small-cell lung cancer.
    Stinchcombe TE; West HL
    Lancet; 2009 Oct; 374(9699):1398-400. PubMed ID: 19767096
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
    Manson GV; Ma PC
    Clin Lung Cancer; 2010 Jan; 11(1):57-60. PubMed ID: 20085869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases.
    Ochi N; Yamane H; Yamagishi T; Takigawa N
    Lung Cancer; 2013 Apr; 80(1):111-3. PubMed ID: 23279874
    [No Abstract]   [Full Text] [Related]  

  • 10. The need for third-line treatment in non-small cell lung cancer: an overview of new options.
    Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F
    Anticancer Res; 2011 Feb; 31(2):649-59. PubMed ID: 21378351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multi-target tumor therapy].
    Krankenpfl J; 2005; 43(1-3):38-9. PubMed ID: 15912831
    [No Abstract]   [Full Text] [Related]  

  • 12. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
    Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
    Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC).
    Mueller E
    Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
    Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant chemotherapy for non-small cell lung cancer.
    D'Amico TA
    Semin Thorac Cardiovasc Surg; 2005; 17(3):195-8. PubMed ID: 16253822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

  • 19. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 20. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.